Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Patent News

New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease

Author(s): Surya K. De*

Volume 31, Issue 33, 2024

Published on: 31 August, 2023

Page: [5477 - 5480] Pages: 4

DOI: 10.2174/0929867331666230821101247

Price: $65

Abstract

This patent describes the novel pyrroloppyrimidine compounds as LRRK2 kinase inhibitors. The patent includes the synthesis of compounds, compositions containing them and their use in the treatment of or prevention of diseases associated with LRRK2 kinase activity, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).

« Previous
[1]
Trinh, J.; Farrer, M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol., 2013, 9(8), 445-454.
[http://dx.doi.org/10.1038/nrneurol.2013.132] [PMID: 23857047]
[2]
Paisán-Ruiz, C.; Lewis, P.A.; Singleton, A.B. LRRK2: Cause, risk, and mechanism. J. Parkinsons Dis., 2013, 3(2), 85-103.
[http://dx.doi.org/10.3233/JPD-130192] [PMID: 23938341]
[3]
Gilks, W.P.; Abou-Sleiman, P.M.; Gandhi, S.; Jain, S.; Singleton, A.; Lees, A.J.; Shaw, K.; Bhatia, K.P.; Bonifati, V.; Quinn, N.P.; Lynch, J.; Healy, D.G.; Holton, J.L.; Revesz, T.; Wood, N.W. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet, 2005, 365(9457), 415-416.
[http://dx.doi.org/10.1016/S0140-6736(05)17830-1] [PMID: 15680457]
[4]
Ross, O.A.; Soto-Ortolaza, A.I.; Heckman, M.G.; Aasly, J.O.; Abahuni, N.; Annesi, G.; Bacon, J.A.; Bardien, S.; Bozi, M.; Brice, A.; Brighina, L.; Van Broeckhoven, C.; Carr, J.; Chartier-Harlin, M.C.; Dardiotis, E.; Dickson, D.W.; Diehl, N.N.; Elbaz, A.; Ferrarese, C.; Ferraris, A.; Fiske, B.; Gibson, J.M.; Gibson, R.; Hadjigeorgiou, G.M.; Hattori, N.; Ioannidis, J.P.A.; Jasinska-Myga, B.; Jeon, B.S.; Kim, Y.J.; Klein, C.; Kruger, R.; Kyratzi, E.; Lesage, S.; Lin, C.H.; Lynch, T.; Maraganore, D.M.; Mellick, G.D.; Mutez, E.; Nilsson, C.; Opala, G.; Park, S.S.; Puschmann, A.; Quattrone, A.; Sharma, M.; Silburn, P.A.; Sohn, Y.H.; Stefanis, L.; Tadic, V.; Theuns, J.; Tomiyama, H.; Uitti, R.J.; Valente, E.M.; van de Loo, S.; Vassilatis, D.K.; Vilariño-Güell, C.; White, L.R.; Wirdefeldt, K.; Wszolek, Z.K.; Wu, R.M.; Farrer, M.J. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: A case–control study. Lancet Neurol., 2011, 10(10), 898-908.
[http://dx.doi.org/10.1016/S1474-4422(11)70175-2] [PMID: 21885347]
[5]
Jaleel, M.; Nichols, R.J.; Deak, M.; Campbell, D.G.; Gillardon, F.; Knebel, A.; Alessi, D.R. LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson’s disease mutants affect kinase activity. Biochem. J., 2007, 405(2), 307-317.
[http://dx.doi.org/10.1042/BJ20070209] [PMID: 17447891]
[6]
Dzamko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 2010, 430(3), 405-413.
[http://dx.doi.org/10.1042/BJ20100784] [PMID: 20659021]
[7]
Guo, L.; Gandhi, P.N.; Wang, W.; Petersen, R.B.; Wilson-Delfosse, A.L.; Chen, S.G. The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Exp. Cell Res., 2007, 313(16), 3658-3670.
[http://dx.doi.org/10.1016/j.yexcr.2007.07.007] [PMID: 17706965]
[8]
West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; Dawson, T.M. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 2007, 16(2), 223-232.
[http://dx.doi.org/10.1093/hmg/ddl471] [PMID: 17200152]
[9]
Wile, D.J.; Agarwal, P.A.; Schulzer, M.; Mak, E.; Dinelle, K.; Shahinfard, E.; Vafai, N.; Hasegawa, K.; Zhang, J.; McKenzie, J.; Neilson, N.; Strongosky, A.; Uitti, R.J.; Guttman, M.; Zabetian, C.P.; Ding, Y.S.; Adam, M.; Aasly, J.; Wszolek, Z.K.; Farrer, M.; Sossi, V.; Stoessl, A.J. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol., 2017, 16(5), 351-359.
[http://dx.doi.org/10.1016/S1474-4422(17)30056-X] [PMID: 28336296]
[10]
Sosero, Y.L.; Gan-Or, Z. LRRK2 and Parkinson’s disease: From genetics to targeted therapy. Ann. Clin. Transl. Neurol., 2023, 10(6), 850-864.
[http://dx.doi.org/10.1002/acn3.51776] [PMID: 37021623]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy